BioMark Diagnostics (20B) Ratios

5 Followers

BioMark Diagnostics Ratios

DE:20B's free cash flow for Q4 2026 was C$-6.75. For the 2026 fiscal year, DE:20B's free cash flow was decreased by C$ and operating cash flow was C$-54.09. See a summary of the company’s cash flow.

Ratios	TTM	Jun 26	Jun 25	Jun 24	Jun 22
Liquidity Ratios
Current Ratio	―	0.99	2.14	0.16	0.33
Quick Ratio	―	0.99	2.14	0.16	0.33
Cash Ratio	―	0.56	2.01	0.13	0.25
Solvency Ratio	―	-0.72	-1.10	-0.61	-0.60
Operating Cash Flow Ratio	―	-0.99	-0.89	-0.79	-0.80
Short-Term Operating Cash Flow Coverage	―	0.00	0.00	-1.33	-8.36
Net Current Asset Value	C$ ―	C$ -445.38K	C$ 1.25M	C$ -1.50M	C$ -1.61M
Leverage Ratios
Debt-to-Assets Ratio	―	0.39	0.14	1.42	0.71
Debt-to-Equity Ratio	―	2.19	0.26	-2.54	-1.65
Debt-to-Capital Ratio	―	0.69	0.21	1.65	2.54
Long-Term Debt-to-Capital Ratio	―	0.00	0.00	0.00	-0.18
Financial Leverage Ratio	―	5.62	1.80	-1.79	-2.31
Debt Service Coverage Ratio	―	-21.55	-23.80	-1.07	-6.58
Interest Coverage Ratio	―	-29.59	-31.01	-11.43	-25.84
Debt to Market Cap	―	0.00	0.00	0.03	0.01
Interest Debt Per Share	―	<0.01	<0.01	0.02	0.02
Net Debt to EBITDA	―	-0.07	1.38	-1.51	-0.54
Profitability Margins
Gross Profit Margin	―	-539.40%	100.00%	100.00%	100.00%
EBIT Margin	―	-3130.74%	-1209.82%	-803.96%	-3196.28%
EBITDA Margin	―	-2491.34%	-949.62%	-563.07%	-2787.41%
Operating Profit Margin	―	-3130.74%	-1237.31%	-806.71%	-2922.50%
Pretax Profit Margin	―	-2681.89%	-1249.73%	-874.52%	-3309.36%
Net Profit Margin	―	-2470.76%	-1249.73%	-874.52%	-3309.36%
Continuous Operations Profit Margin	―	-2470.76%	-1249.73%	-874.52%	-3309.36%
Net Income Per EBT	―	92.13%	100.00%	100.00%	100.00%
EBT Per EBIT	―	85.66%	101.00%	108.40%	113.24%
Return on Assets (ROA)	―	-79.40%	-61.49%	-131.08%	-98.80%
Return on Equity (ROE)	―	-446.20%	-110.70%	234.15%	228.71%
Return on Capital Employed (ROCE)	―	-245.47%	-100.34%	847.04%	4328.72%
Return on Invested Capital (ROIC)	―	-163.31%	-86.93%	-140.65%	-310.35%
Return on Tangible Assets	―	-79.40%	-61.49%	-131.08%	-98.80%
Earnings Yield	―	-2.47%	-8.37%	-5.58%	-8.74%
Efficiency Ratios
Receivables Turnover	―	1.19	0.96	3.79	0.53
Payables Turnover	―	3.80	0.00	0.00	0.00
Inventory Turnover	―	0.00	0.00	0.00	0.00
Fixed Asset Turnover	―	0.08	0.34	0.19	0.05
Asset Turnover	―	0.03	0.05	0.15	0.03
Working Capital Turnover Ratio	―	0.09	0.84	-0.13	-0.09
Cash Conversion Cycle	―	211.03	380.26	96.22	682.34
Days of Sales Outstanding	―	307.19	380.26	96.22	682.34
Days of Inventory Outstanding	―	0.00	0.00	0.00	0.00
Days of Payables Outstanding	―	96.17	0.00	0.00	0.00
Operating Cycle	―	307.19	380.26	96.22	682.34
Cash Flow Ratios
Operating Cash Flow Per Share	―	-0.01	-0.01	-0.01	-0.02
Free Cash Flow Per Share	―	-0.01	-0.01	-0.01	-0.02
CapEx Per Share	―	<0.01	<0.01	<0.01	<0.01
Free Cash Flow to Operating Cash Flow	―	1.00	1.00	1.00	1.05
Dividend Paid and CapEx Coverage Ratio	―	-257.40	-309.40	-223.61	-20.34
Capital Expenditure Coverage Ratio	―	-257.40	-309.40	-223.61	-20.34
Operating Cash Flow Coverage Ratio	―	-1.50	-2.41	-0.64	-1.15
Operating Cash Flow to Sales Ratio	―	-18.21	-7.09	-6.02	-27.40
Free Cash Flow Yield	―	-1.82%	-4.77%	-3.86%	-7.59%
Valuation Ratios
Price-to-Earnings (P/E) Ratio	―	-40.43	-11.95	-17.91	-11.44
Price-to-Sales (P/S) Ratio	―	1.00K	149.23	156.67	378.58
Price-to-Book (P/B) Ratio	―	180.94	13.22	-41.95	-26.16
Price-to-Free Cash Flow (P/FCF) Ratio	―	-54.80	-20.99	-25.91	-13.17
Price-to-Operating Cash Flow Ratio	―	-55.02	-21.05	-26.03	-13.81
Price-to-Earnings Growth (PEG) Ratio	―	1.07	-0.34	0.71	-0.33
Price-to-Fair Value	―	180.94	13.22	-41.95	-26.16
Enterprise Value Multiple	―	-40.29	-14.33	-29.34	-14.13
Enterprise Value	―	60.01M	20.99M	26.96M	17.30M
EV to EBITDA	―	-40.29	-14.33	-29.34	-14.13
EV to Sales	―	1.00K	136.09	165.18	393.76
EV to Free Cash Flow	―	-54.90	-19.14	-27.32	-13.70
EV to Operating Cash Flow	―	-55.11	-19.20	-27.44	-14.37
Tangible Book Value Per Share	―	<0.01	0.02	>-0.01	>-0.01
Shareholders’ Equity Per Share	―	<0.01	0.02	>-0.01	>-0.01
Tax and Other Ratios
Effective Tax Rate	―	0.08	0.00	0.00	-0.03
Revenue Per Share	―	<0.01	<0.01	<0.01	<0.01
Net Income Per Share	―	-0.01	-0.02	-0.02	-0.02
Tax Burden	―	0.92	1.00	1.00	1.00
Interest Burden	―	0.86	1.03	1.09	1.04
Research & Development to Revenue	―	11.17	4.51	3.99	11.33
SG&A to Revenue	―	14.74	6.48	4.44	19.66
Stock-Based Compensation to Revenue	―	0.00	2.38	0.46	0.00
Income Quality	―	0.74	0.57	0.69	0.83

Currency in CAD